$8.30
At close: Apr 30 EDT
$8.30
0.000.00%
Pre-Market: 4:21 PM EDT
Comments
Loading...
Ocular Therapeutix Analyst Ratings and Price Targets | NASDAQ:OCUL | Benzinga
Ocular Therapeutix Inc has a consensus price target of $16.42 based on the ratings of 13 analysts. The high is $22 issued by Scotiabank on October 16, 2024. The low is $11 issued by TD Cowen on June 20, 2024. The 3 most-recent analyst ratings were released by Needham, RBC Capital, and Needham on April 8, 2025, March 18, 2025, and March 11, 2025, respectively. With an average price target of $15.67 between Needham, RBC Capital, and Needham, there's an implied 88.76% upside for Ocular Therapeutix Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
RBC Capital
Citizens Capital Markets
HC Wainwright & Co.
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Ocular Therapeutix
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | — | William Blair | Lachlan Brown25% | — | Initiates | → Outperform | Get Alert |
| 04/08/2025 | Buy Now | 80.72% | Needham | Serge Belanger69% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2025 | Buy Now | 104.82% | RBC Capital | Luca Issi40% | → $17 | Initiates | → Outperform | Get Alert |
| 03/11/2025 | Buy Now | 80.72% | Needham | Serge Belanger69% | → $15 | Initiates | → Buy | Get Alert |
| 03/04/2025 | Buy Now | 128.92% | Citizens Capital Markets | Jonathan Wolleben68% | $22 → $19 | Maintains | Market Outperform | Get Alert |
| 03/04/2025 | Buy Now | 80.72% | HC Wainwright & Co. | Yi Chen57% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 12/03/2024 | Buy Now | 80.72% | HC Wainwright & Co. | Yi Chen57% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 80.72% | HC Wainwright & Co. | Yi Chen57% | $14 → $15 | Maintains | Buy | Get Alert |
| 10/16/2024 | Buy Now | 165.06% | Scotiabank | Greg Harrison46% | → $22 | Initiates | → Sector Outperform | Get Alert |
| 10/16/2024 | Buy Now | 68.67% | HC Wainwright & Co. | Yi Chen57% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | 104.82% | Baird | Colleen Kusy34% | $18 → $17 | Maintains | Outperform | Get Alert |
| 08/01/2024 | Buy Now | 68.67% | HC Wainwright & Co. | Yi Chen57% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2024 | Buy Now | 80.72% | Piper Sandler | Biren Amin41% | $15 → $15 | Maintains | Overweight | Get Alert |
| 06/20/2024 | Buy Now | 32.53% | TD Cowen | Tara Bancroft59% | $7 → $11 | Upgrade | Hold → Buy | Get Alert |
| 06/14/2024 | Buy Now | 80.72% | Piper Sandler | Joseph Catanzaro43% | $15 → $15 | Maintains | Overweight | Get Alert |
| 06/14/2024 | Buy Now | 68.67% | HC Wainwright & Co. | Yi Chen57% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 68.67% | HC Wainwright & Co. | Yi Chen57% | $16 → $14 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 165.06% | JMP Securities | Jonathan Wolleben68% | $24 → $22 | Maintains | Market Outperform | Get Alert |
| 05/08/2024 | Buy Now | -15.66% | TD Cowen | Tara Bancroft59% | $11 → $7 | Maintains | Hold | Get Alert |
| 04/19/2024 | Buy Now | 92.77% | HC Wainwright & Co. | Yi Chen57% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | 189.16% | JMP Securities | Jonathan Wolleben68% | $24 → $24 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/13/2024 | Buy Now | 189.16% | JMP Securities | Jonathan Wolleben68% | $24 → $24 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/13/2024 | Buy Now | 80.72% | HC Wainwright & Co. | Yi Chen57% | $12 → $15 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 32.53% | TD Cowen | Tara Bancroft59% | $8 → $11 | Maintains | Market Perform | Get Alert |
| 03/12/2024 | Buy Now | 189.16% | JMP Securities | Jonathan Wolleben68% | $12 → $24 | Maintains | Market Outperform | Get Alert |
| 02/26/2024 | Buy Now | 80.72% | Piper Sandler | Joseph Catanzaro43% | $10 → $15 | Maintains | Overweight | Get Alert |
| 02/14/2024 | Buy Now | 44.58% | HC Wainwright & Co. | Yi Chen57% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 02/09/2024 | Buy Now | 80.72% | B of A Securities | Tazeen Ahmad55% | → $15 | Initiates | → Buy | Get Alert |
| 10/04/2023 | Buy Now | 44.58% | HC Wainwright & Co. | Yi Chen57% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 116.87% | Baird | Colleen Kusy34% | → $18 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2023 | Buy Now | 44.58% | HC Wainwright & Co. | Yi Chen57% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 06/13/2023 | Buy Now | 44.58% | Baird | Colleen Kusy34% | $10 → $12 | Maintains | Outperform | Get Alert |
| 06/13/2023 | Buy Now | 44.58% | JMP Securities | Jonathan Wolleben68% | → $12 | Reiterates | → Market Outperform | Get Alert |
| 06/13/2023 | Buy Now | 44.58% | HC Wainwright & Co. | Yi Chen57% | $10 → $12 | Maintains | Buy | Get Alert |
| 06/08/2023 | Buy Now | 20.48% | HC Wainwright & Co. | Yi Chen57% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2023 | Buy Now | 20.48% | HC Wainwright & Co. | Yi Chen57% | $11 → $10 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 44.58% | JMP Securities | Jonathan Wolleben68% | $11 → $12 | Maintains | Outperform | Get Alert |
| 04/21/2023 | Buy Now | 116.87% | Baird | Colleen Kusy34% | → $18 | Initiates | → Outperform | Get Alert |
| 03/07/2023 | Buy Now | 32.53% | HC Wainwright & Co. | Yi Chen57% | → $11 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 32.53% | JMP Securities | Jonathan Wolleben68% | $12 → $11 | Maintains | Market Outperform | Get Alert |
| 02/14/2023 | Buy Now | 32.53% | HC Wainwright & Co. | Yi Chen57% | $9 → $11 | Maintains | Buy | Get Alert |
| 02/13/2023 | Buy Now | 44.58% | JMP Securities | Jonathan Wolleben68% | → $12 | Reiterates | → Market Outperform | Get Alert |
| 01/09/2023 | Buy Now | 44.58% | JMP Securities | Jonathan Wolleben68% | $25 → $12 | Maintains | Market Outperform | Get Alert |
| 11/08/2022 | Buy Now | 8.43% | HC Wainwright & Co. | Yi Chen57% | $10 → $9 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | 68.67% | Raymond James | Dane Leone46% | $29 → $14 | Maintains | Strong Buy | Get Alert |
| 08/09/2022 | Buy Now | 201.2% | JMP Securities | Jonathan Wolleben68% | $20 → $25 | Maintains | Market Outperform | Get Alert |
| 05/10/2022 | Buy Now | 140.96% | JMP Securities | Jonathan Wolleben68% | $22 → $20 | Maintains | Market Outperform | Get Alert |
| 05/10/2022 | Buy Now | 20.48% | HC Wainwright & Co. | Yi Chen57% | $14 → $10 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | 92.77% | Piper Sandler | Joseph Catanzaro43% | $20 → $16 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Ocular Therapeutix (OCUL) stock?
The latest price target for Ocular Therapeutix (NASDAQ:OCUL) was reported by William Blair on April 8, 2025. The analyst firm set a price target for $0.00 expecting OCUL to fall to within 12 months (a possible -100.00% downside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ocular Therapeutix (OCUL)?
The latest analyst rating for Ocular Therapeutix (NASDAQ:OCUL) was provided by William Blair, and Ocular Therapeutix initiated their outperform rating.
When was the last upgrade for Ocular Therapeutix (OCUL)?
The last upgrade for Ocular Therapeutix Inc happened on June 20, 2024 when TD Cowen raised their price target to $11. TD Cowen previously had a hold for Ocular Therapeutix Inc.
When was the last downgrade for Ocular Therapeutix (OCUL)?
There is no last downgrade for Ocular Therapeutix.
When is the next analyst rating going to be posted or updated for Ocular Therapeutix (OCUL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocular Therapeutix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocular Therapeutix was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating Ocular Therapeutix (OCUL) correct?
While ratings are subjective and will change, the latest Ocular Therapeutix (OCUL) rating was a initiated with a price target of $0.00 to $0.00. The current price Ocular Therapeutix (OCUL) is trading at is $8.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
